An Analysis of Our Ten-Year Cohort of Patients with Cardiac Amyloidosis Supported by the Continuous-Flow Left Ventricular Assist Device

Limited data exists on the use continuous-flow left ventricular assist device (CF-LVAD) in patients with cardiac amyloidosis (CA). The largest single center analysis on CF-LVAD support in patients with CA reports a 50% mortality at 6-months. Our primary aim was to examine the survival and morbidity of our patients with diagnosed CA and supported by CF-LVAD.

Source: The Journal of Heart and Lung Transplantation - March 31, 2020 Category: Transplant Surgery Authors: V.K. Randhawa, A. Gabrovsek, E.G. Soltesz, M.Z. Tong, S. Unai, L. Chen, M.M. Mountis, J.D. Estep, W. Tang, M. Hanna Tags: (1086) Source Type: research